NeuroMAP Phase II - Circuits and Molecules Core

项目概要：电路和分子核心 神经科学为基础的心理健康评估中心的电路和分子（C & M）核心， 第二阶段的预测（NeuroMAP）将支持研究项目负责人（RPL）和试点项目 研究者（PPI）通过监督生物样本的采集、储存和分析， 神经成像数据。C & M核心的第一个目标是通过以下方式加快RPL和PPI项目：（a）提供 神经影像学和分子生物学方面的必要专业知识，以确保NeuroMAP项目的成功 以及（B）基于共同核心数据元素（CDE）帮助制定新的目标和假设， 使R级补助金申请更具竞争力。C & M Core的第二个目标是发展自给自足 以便它最终能够成为更广泛的地理区域的资源。为了实现这一目标，C & M 核心将制定一个详细的商业计划与成本估计，以支持可持续性超出了CoBRE。 C & M核心将与招聘和评估核心以及数据管理和 统计核心支持NeuroMAP主题：识别和验证，通过实验 方法，有针对性的疾病修饰过程（DMPs）的情绪和焦虑症。在第一阶段，a 在所有项目中建立了一套CDE，并在项目的研究目标之间提供了平衡。 个别过往资历认可计划及生产者价格指数的二手数据分析。在此期间，超过350 获得神经影像学评估，包括标准结构MRI、扩散张量成像、 静息状态MRI和几个功能性MRI任务。同样，来自350多名参与者的血液样本被 收集以测量一系列循环炎症介质。在第二阶段，C & M核心将与 招募和评估核心收集新的成像和实验室数据集，可用于 RPL扩展其项目和PPI，以确定新的DMP。影像学和实验室检查结果如下： 被选择来描述具有情绪和焦虑障碍的个体的过程功能障碍， 价结构域，即，个体如何对令人厌恶的情境作出反应，（B）正配价域，即，如何 个体对积极的环境作出反应，以及（c）内感受域，即，身体内部的处理 影响行为的信号。这些措施将在第二阶段得到优化。高级序列测量 髓磷脂含量和神经炎症（限制性扩散成像）将添加到Circuit组件中 而分子部分将专注于测量星形胶质细胞的microRNA和蛋白质- 丰富的细胞外囊泡（EV），建立在我们最近在这一领域的出版物。C & M核心将由 由联合主任罗汉博士和萨维茨博士在阿特伯里女士、伯罗斯博士和美崎博士的支持下编写。Drs. Savitz和Burrows（分子部分）还将与综合研究中心主任蒂格博士密切联系。 俄克拉荷马州大学免疫学中心。

PROJECT SUMMARY: Circuits and Molecules Core The Circuits and Molecules (C&M) Core of the Center for Neuroscience-based Mental Health Assessment and Prediction (NeuroMAP) in Phase II will support Research Project Leaders (RPLs) and Pilot Project Investigators (PPIs) by overseeing the acquisition, storage, and analysis of biological samples and neuroimaging data. The first goal of the C&M Core is to accelerate the RPL and PPI projects by (a) providing the necessary expertise in neuroimaging and molecular biology to ensure the success of NeuroMAP projects and (b) aiding in the formulation of new aims and hypotheses based on common core data elements (CDE) to make R-level grant applications more competitive. The second goal of C&M Core is to develop self-sufficiency so that it can ultimately serve as a resource for the broader geographical region. To achieve this goal, the C&M Core will develop a detailed business plan with cost estimates to support sustainability beyond the CoBRE. The C&M Core will work together with the Recruitment and Assessment Core and the Data Management and Statistics Core to support the NeuroMAP theme: the identification and validation, via an experimental approach, of targetable disease-modifying processes (DMPs) in mood and anxiety disorders. During Phase I, a set of CDE was established across all projects and provided a balance between the research goals of the individual RPL projects and secondary data analyses for PPIs. During that Phase, more than 350 neuroimaging assessments were obtained consisting of a standard structural MRI, diffusion tensor imaging, a resting state MRI, and several functional MRI tasks. Similarly, blood samples from over 350 participants were collected to measure a range of circulating inflammatory mediators. In Phase II, the C&M Core will work with the Recruitment and Assessment Core to collect a new imaging and laboratory data set that can be used by RPLs to extend their projects and PPIs to identify new DMPs. The imaging and laboratory measures were selected to delineate process dysfunctions by individuals with mood and anxiety disorders in the (a) Negative Valence domain i.e., how individuals respond to aversive contexts, (b) Positive Valence domain i.e., how individuals respond to positive contexts and (c) Interoception domain i.e., the processing of internal bodily signals to affect behavior. These measures will be optimized in Phase II. Advanced sequences to measure myelin content and neuroinflammation (restricted diffusion imaging) will be added to the Circuit component while the Molecules component will focus on the measurement of microRNA and proteins from astrocyte- enriched extracellular vesicles (EVs), building on our recent publications in this area. The C&M Core will be led by Co-Directors, Drs. Rohan and Savitz with the support of Ms. Arterbury and Drs. Burrows and Misaki. Drs. Savitz and Burrows (molecules component) will also liaise closely with Dr. Teague, director of the Integrative Immunology Center at the University of Oklahoma.